Hepatitis C Virus (hcv) Protease Inhibitors - Infectious Diseases

Relevant Publications

Vesicular Stomatitis Virus as a Platform for Protease Activity Measurements.

Issue Release: 2024

Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.

Issue Release: 2024

Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients.

Issue Release: 2024

Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review.

Issue Release: 2024

Replicative co-infections with human immunodeficiency virus 1 and 2 as well as hepatitis B and C virus in Ghanaian individuals.

Issue Release: 2024

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.

Issue Release: 2023

Computational medicinal chemistry applications to target Asian-prevalent strain of hepatitis C virus.

Issue Release: 2023

Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus.

Issue Release: 2023

Virological characterization of treatment failures and retreatment outcomes in patients infected with \"unusual\" HCV genotype 1 subtypes.

Issue Release: 2023

Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.

Issue Release: 2023

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.

Issue Release: 2022

Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.

Issue Release: 2022

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease.

Issue Release: 2022

Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.

Issue Release: 2022

Relationship between phase angle, steatosis, and liver fibrosis in patients coinfected with human immunodeficiency virus/hepatitis C virus.

Issue Release: 2022

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization.

Issue Release: 2022

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.

Issue Release: 2022

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report.

Issue Release: 2022

Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.

Issue Release: 2022

Antivirals against HCV infection: the story thus far.

Issue Release: 2022

What Treatments are Available?

What Are the Challenges in Targeting Glycolysis?

What are the Challenges in Treating Sporozoite-Related Infections?

How is Malaria Diagnosed?

What are the benefits of Dengvaxia?

What Are the Main Treatment Options?

How is Lyme Disease Transmitted?

Why is One Health Important in Infectious Diseases?

What is Plasmodium?

What is Salmonella?

Partnered Content Networks

Relevant Topics